department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

VIGABATRIN · pharmadog

pharmadog
drugs
VIGABATRIN

patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

← back to professional view

drug

VIGABATRIN

Marketedupdated 2mo ago

by Novadoz Pharmaceuticals LLC

Approved

community read0 votes

all catalysts(100)

approval · 100

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

view all 100 catalysts →

News(0)

no news has mentioned this drug yet

brand

VIGABATRIN

generic

VIGABATRIN

indication

Complex Partial Seizure

phase

marketed

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

VIGADRONE (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

VIGADRONE (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

VIGADRONE (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

VIGADRONE (VIGABATRIN) — FDA approval

VIGABATRIN — FDA approval

VIGADRONE (VIGABATRIN) — FDA approval

VIGABATRIN — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

SABRIL (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGADRONE (VIGABATRIN) — FDA approval

VIGADRONE (VIGABATRIN) — FDA approval

VIGADRONE (VIGABATRIN) — FDA approval

VIGADRONE (VIGABATRIN) — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

SABRIL (VIGABATRIN) — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGADRONE (VIGABATRIN) — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

SABRIL (VIGABATRIN) — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

SABRIL (VIGABATRIN) — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGADRONE (VIGABATRIN) — FDA approval

SABRIL (VIGABATRIN) — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

VIGADRONE (VIGABATRIN) — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

SABRIL (VIGABATRIN) — FDA approval

VIGABATRIN — FDA approval

SABRIL (VIGABATRIN) — FDA approval

VIGABATRIN — FDA approval

VIGABATRIN — FDA approval

Data sources

openFDA · ClinicalTrials.gov

last refreshed 39m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 16, 2039

~13.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

Jun 8, 2043formulationUS 12576054
Oct 17, 2042formulationUS 12290499
Aug 16, 2039formulationUS 12016857

🐶 often sniffed alongside

top 7

tagApproval388 co-mentions · 194 sources
drugSABRIL239 co-mentions · 194 sources
drugVIGADRONE206 co-mentions · 194 sources
drugVigafyde199 co-mentions · 194 sources
tagSmall Molecule194 co-mentions · 194 sources
companyAurobindo Pharma Ltd9 co-mentions · 9 sources
companyZydus Lifesciences Ltd7 co-mentions · 7 sources

Trials studying VIGABATRIN

phase3A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasmsterminatedn=2